Standard Therapy: Clinical Trials

20 trials of Standard Therapy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed, 6 withdrawn, 1 terminated, 1 unknown. 20 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 420Completed 12, Withdrawn 6, Terminated 1, Unknown 1

Follow Standard Therapy: new trials by email Literature Review of Standard Therapy trials Research Report on Standard Therapy

Trials (filtered) newest first · largest first

All 20 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Mexidol® Efficacy and Safety in Treatment of VCIND in Older Adults
Mexidol, Standard Therapy - Vascular Cognitive Impairment no Dementia
Phase 4CompletedPharmasoft1202025-09-142026-07-14
Suvorexant for Insomnia to Prevent Delirium in Hospitalized Cancer Patients
Best Practice, Electronic Health Record Review, Interview - Advanced Malignant Solid Neoplasm, Delirium
Phase 4WithdrawnMayo Clinic2025-02-262025-05-01
The Efficacy of Self-Manufactured 40% Dextrose Gel in Asymptomatic Transient Neonatal Hypoglycemia Treatment
self-manufactured 40% dextrose gel, Standard therapy - Neonatal Hypoglycemia
Phase 4CompletedUniversitas Indonesia1332023-05-012025-06-11
Efficacy of Intravenous Amboxol Hydrochloride as an Adjunct Therapy for Severe Pneumonia in Critically Ill Patients
Ambroxol Hydrochloride, Standard Therapy - Severe Pneumonia, Community-acquired Pneumonia
Phase 4CompletedNational University of Malaysia322023-01-072023-12-27
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.
Aerosolized 13 cis retinoic acid plus Vitamin D, Aerosolized All trans retinoic acid plus Vitamin D, Standard therapy - Post COVID-19 Anosmia (Loss of Smell)
Phase 4UnknownKafrelsheikh University100002021-11-012021-11-11
Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE)
Belimumab, Standard therapy - Systemic Lupus Erythematosus
Phase 4CompletedGlaxoSmithKline672021-10-212026-05-11
Micronized and Ultramicronized Palmitoylethanolamide in COVID-19 Patients
Micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) oral suspension, Standard Therapy - Covid19
Phase 4CompletedEpitech Group SpA402020-10-232021-08-25
Micronized and Ultramicronized Palmitoylethanolamide in Fibromyalgia Patients
micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) microgranules, Placebo microgranules 1800mg, Standard Therapy - Fibromyalgia
Phase 4CompletedEpitech Group SpA212020-07-162023-09-07
Improving Pain Management After Total Shoulder Replacement Using Bupivacaine Liposome
Bupivacaine Liposome Injection, Standard Therapy - Osteoarthritis of the Shoulder, Shoulder Pain
Phase 4WithdrawnUniversity of Massachusetts, Worcester2019-12-092022-07-06
A Randomized Trial of Rosuvastatin Loading Combined With Early hydrAtion Versus Standard-of-care Medications for the Prevention of CIAKI in Patient With AMI Undergoing Emergency PCI
hydration plus rosuvastatin therapy, Standard therapy - Contrast-induced Acute Kidney Injury, ST Elevation Myocardial Infarction
Phase 4WithdrawnShenyang Northern Hospital2019-02-202019-09-19
Adjunctive 5% Lidocaine Patches for Acute Non-radicular Low Back Pain in Emergency Department Patients
lidocaine 5% patch, standard therapy, Non-medicated patch - Low Back Pain
Phase 4WithdrawnCook County Health2017-03-102023-06-29
SMOFLipid in Patients Who Are Intralipid Intolerant
SMOFLipid, Standard therapy - Home Parenteral Nutrition, Short Bowel Syndrome
Phase 4WithdrawnMayo Clinic2017-02-012018-03-22
Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers
Varenicline, BASC, Standard treatment - Nicotine Dependence, Major Depressive Disorder
Phase 4CompletedNorthwestern University3002015-07-242021-07-29
EARly Prevention of aTHeroma Progression
Standard Therapy, Rosuvastatin - Coronary Arteriosclerosis
Phase 4TerminatedCHEOL WHAN LEE, M.D., Ph.D1112014-06-012018-06-25
Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)
Placebo plus standard therapy, Belimumab 10 mg/kg plus standard therapy, Standard therapy - Systemic Lupus Erythematosus
Phase 4CompletedHuman Genome Sciences Inc., a GSK Company5032013-02-192021-09-08
Belimumab Assessment of Safety in SLE
Placebo plus standard therapy, Belimumab 10 mg/kg plus standard therapy, Standard therapy - Systemic Lupus Erythematosus
Phase 4CompletedGlaxoSmithKline40192012-11-272024-07-15
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
Zoledronic acid, Standard Therapy - First or Second Line HER2-negative Breast Cancer, Metastatic Disease Without Bone Metastasis
Phase 4CompletedNovartis Pharmaceuticals442010-06-012014-05-20
Radical Prostatectomy and Perioperative Fluid Therapy
Standard therapy, Maximization of cardiac stroke volume with fluid infusion - Prostate Cancer
Phase 4CompletedCopenhagen University Hospital, Rigshospitalet442008-10-012012-10-22
Syphilis Response to Higher Penicillin Dosage: The 2.4 Versus 7.2 Study
Benzathine penicillin G intramuscular 7.2 million units, Benzathine penicillin G intramuscular 2.4 million units - Syphilis
Phase 4CompletedBaylor College of Medicine642008-09-012016-05-17
Ziprasidone vs Standard Therapy for Agitated Patients in the ED
ziprasidone, Standard therapy - Psychosis, Agitation
Phase 4WithdrawnGeorge Washington University2008-09-012017-09-25

Conditions studied

Lupus Erythematosus, Systemic (3)  ·  Autoimmune Diseases (2)  ·  Delirium (2)  ·  Agnosia (1)  ·  Anosmia (1)  ·  Breast Neoplasms (1)  ·  COVID-19 (1)  ·  Cigarette Smoking (1)  ·  Cognitive Dysfunction (1)  ·  Community-Acquired Pneumonia (1)  ·  Coronary Artery Disease (1)  ·  Critical Illness (1)  ·  Depressive Disorder, Major (1)  ·  Fibromyalgia (1)  ·  Healthcare-Associated Pneumonia (1)

Sponsors

Epitech Group SpA (2)  ·  GlaxoSmithKline (2)  ·  Mayo Clinic (2)  ·  Baylor College of Medicine (1)  ·  CHEOL WHAN LEE, M.D., Ph.D (1)  ·  Cook County Health (1)  ·  Copenhagen University Hospital, Rigshospitalet (1)  ·  George Washington University (1)  ·  Human Genome Sciences Inc., a GSK Company (1)  ·  Kafrelsheikh University (1)  ·  National University of Malaysia (1)  ·  Northwestern University (1)  ·  Novartis Pharmaceuticals (1)  ·  Pharmasoft (1)  ·  Shenyang Northern Hospital (1)

Countries

United States (9)  ·  China (3)  ·  Italy (3)  ·  Brazil (2)  ·  Colombia (2)  ·  Indonesia (2)  ·  Malaysia (2)  ·  Russia (2)  ·  South Korea (2)  ·  Argentina (1)  ·  Australia (1)  ·  Bulgaria (1)  ·  Canada (1)  ·  Chile (1)  ·  Croatia (1)

Top investigators

Alexander Chan, MD (1)  ·  Brian Hitsman, Ph.D. (1)  ·  Enrico Polati, MD (1)  ·  Jose A Serpa-Alvarez, MD (1)  ·  Mahmoud Elkazzaz, M.Sc of Biochemistry (1)  ·  Manpreet S Mundi (1)  ·  Prof.ssa Flaminia Coluzzi, MD (1)  ·  Regina M. Mackey, MD (1)  ·  Tamer Haydara, Ass/Prof of Internal medicine (1)  ·  Yaling Han, MD (1)

Results publications

PMID 21357346, PMID 22727868, PMID 24075361, PMID 25819173, PMID 25957977, PMID 26500974, PMID 27441006, PMID 27605513, PMID 28200045, PMID 28364046, PMID 28764827, PMID 29579758, PMID 29702618, PMID 31556318, PMID 33107014, PMID 33489995, PMID 33752207, PMID 34164944, PMID 34353586, PMID 34531304, PMID 34627324, PMID 36792172, PMID 37069490, PMID 37119868, PMID 37934573, PMID 37943674, PMID 38279368, PMID 38724182, PMID 38775637, PMID 39115551, PMID 39208825, PMID 8466261

NIH funding

R01CA184211 (1)